Skip to main content

Table 3 Proportion of patients achieving clinical response at 6 months and 1 year (according to ACR20, ACR50 and ACR70 criteria)

From: Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

 

Overall

Secukinumab

TNFis

n (%)

n (%)

n (%)

6 months

 ACR20 response

n = 194

n = 75

n = 105

80 (41.2%)

34 (45.3%)

41 (39.0%)

 ACR50 response

n = 194

n = 75

n = 105

57 (29.4%)

25 (33.3%)

28 (26.7%)

 ACR70 response

n = 199

n = 77

n = 108

34 (17.1%)

14 (18.2%)

18 (16.7%)

12 months

 ACR20 response

n = 189

n = 74

n = 100

66 (34.9%)

26 (35.1%)

36 (36.0%)

 ACR50 response

n = 191

n = 75

n = 101

51 (26.7%)

22 (29.3%)

26 (25.7%)

 ACR70 response

n = 196

n = 76

n = 105

36 (18.4%)

13 (17.1%)

21 (20.0%)

  1. Percentages calculated over the total number of patients with available evaluation of ACR at each time point (n is indicated in the table)